PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

NCT05229315 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
T2-3N0 or T1-2N1
EBV-DNA≤4000 Copy/ml

Interventions

DRUG: Toripalimab
PROCEDURE: Intensity modulated radiotherapy

Sponsor

XIANG YANQUN